The emergence of drug-resistant bacteria is a huge and threatening problem, yet the pharmaceutical and venture capital industries have not stepped forward to address it. Why is that, and what can be done from a public policy point of view? Hear from experts who are on the front lines of antibiotic development.
This study group / discussion is open to all. Registration is not necessary.M-RCBG welcomes individuals with disabilities to participate in its programs. To request accommodations or ask questions about access provided, please email: email@example.com
Speakers and Presenters
Eric Evans: M-RCBG Senior Fellow